← Back to Clinical Trials
Recruiting NCT07171658

NCT07171658 Breast Cancer-Related Approach for Increasing Cervical Cancer Screening

◆ AI Clinical Summary
Plain-language summary for patients
Clinical Trial Summary
NCT ID NCT07171658
Status Recruiting
Phase
Sponsor Jessica Di Vincenzo Sormani
Condition Cervical Cancer Screening
Study Type INTERVENTIONAL
Enrollment 4,500 participants
Start Date 2025-10-07
Primary Completion 2027-12-31

Eligibility & Interventions

Sex Female only
Min Age 50 Years
Max Age 74 Years
Study Type INTERVENTIONAL
Interventions
Sensitization to Cervical Cancer (CC) screeningHome-based HPV self-sampling

Eligibility Fast-Check

Enter your details for a quick preliminary check. This does not replace medical advice.

What to Expect as a Participant

You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.

This trial targets 4,500 participants in total. It began in 2025-10-07 with a primary completion date of 2027-12-31.

⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.

Brief Summary

The primary objective of this clinical trial is to assess cervical cancer screening participation among under-screened women invited through organized breast cancer screening programs in Switzerland. This randomized trial will compare three arms: 1. Intervention group 1: Sensitization to Cervical Cancer (CC) screening Women will receive an awareness letter explaining the importance of cervical cancer screening, the Swiss recommendations and an invitation to schedule an appointment. 2. Intervention group 2: Home-based Human papillomavirus infection (HPV) self-sampling Women will receive a free-of-charge vaginal self-sampling kit for HPV infection 3. Observational control group Women selected in the control arm will only be recruited one year following the screening of those in the intervention arm (T0+1), as to not influence Cervical Cancer Screening (CCS) behavior during this period by being reminded of screening recommendations.

Eligibility Criteria

Inclusion Criteria: * Women receiving Breast Cancer Screening (BCS) invitation letters in the selected five cantons (Geneva, Bern (francophone), Jura, Neuchâtel, and Vaud) * Aged 50 to 74 years old * Not been screened for cervical cancer in the past three years * Speaking one of the 6 languages of the study (French, German, Italian, and in English, Spanish, and Portuguese) Exclusion Criteria: * Prior cervical cancer diagnosis, * Hysterectomy * Non consent to participate to the study * Incapable of judgment or under tutelage * Pregnancy

Contact & Investigator

Central Contact

Jessica Di Vincenzo-Sormani, PhD

✉ jessica.di-vincenzo-sormani@hesge.ch

📞 +41 22 558 58 78

Principal Investigator

Jessica Di Vincenzo Sormani, PhD

STUDY DIRECTOR

Haute École de Santé de Genève (HEdS-GE)

Frequently Asked Questions

Who can join the NCT07171658 clinical trial?

This trial is open to female participants only, aged 50 Years or older, up to 74 Years, studying Cervical Cancer Screening. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.

Is NCT07171658 currently recruiting?

Yes, NCT07171658 is actively recruiting participants. Contact the research team at jessica.di-vincenzo-sormani@hesge.ch for enrollment information.

Where is the NCT07171658 trial being conducted?

This trial is being conducted at Geneva, Switzerland.

Who is sponsoring the NCT07171658 clinical trial?

NCT07171658 is sponsored by Jessica Di Vincenzo Sormani. The principal investigator is Jessica Di Vincenzo Sormani, PhD at Haute École de Santé de Genève (HEdS-GE). The trial plans to enroll 4,500 participants.

Related Trials

Related Intelligence Guides

In-depth guides covering this condition's trials, eligibility, and what to expect.

ClinicalMetric — Independent clinical trial intelligence platform. Not affiliated with NIH, ClinicalTrials.gov, the U.S. FDA, or any pharmaceutical company, hospital, or clinical research organization. Trial data is sourced from ClinicalTrials.gov for informational purposes only and does not constitute medical advice. Do not make any treatment, enrollment, or health decisions based solely on information found here — always consult a qualified healthcare professional. Full Disclaimer  ·  Last Reviewed: April 2026  ·  Data Methodology